Science and Clinical Pharmacy Research Journal Vol: 2, No 4, 2026, Page: 1-10

Digital Transformation in Pharmaceutical Manufacturing Processes Based on Good Manufacturing Practice

Susilowati Andari

AkafarmaSunan Giri Ponorogo

Abstrak: Penelitian ini bertujuan untuk menganalisis peran transformasi digital dalam proses manufaktur farmasi berdasarkan *Good Manufacturing Practice* (GMP) dengan fokus pada kontribusinya terhadap peningkatan kualitas, efisiensi operasional, dan kepatuhan regulasi. Penelitian ini menggunakan pendekatan kualitatif dengan metode deskriptif melalui tinjauan literatur, yang melibatkan analisis artikel ilmiah, laporan resmi, dan dokumen akademik relevan yang diterbitkan antara tahun 2015 dan 2025. Teknik pengumpulan data dilakukan melalui pencarian sistematis literatur dari berbagai basis data akademik, sementara analisis data dilakukan melalui tahap identifikasi tema, reduksi data, kategorisasi konsep, dan penarikan kesimpulan induktif. Hasil penelitian menunjukkan bahwa integrasi teknologi digital seperti Kecerdasan Buatan (AI), Internet of Things (IoT), blockchain, digital twins, dan analisis big data secara signifikan meningkatkan efektivitas implementasi GMP dengan memperkuat integritas data, mempercepat pengambilan keputusan berbasis data, dan meningkatkan transparansi rantai pasok farmasi. Namun, hambatan seperti resistensi organisasi, keterbatasan integrasi sistem legacy, dan masalah keamanan siber tetap menjadi tantangan utama dalam implementasinya. Secara teoritis, penelitian ini memperluas pemahaman tentang evolusi sistem kualitas berbasis digital di industri farmasi, sementara secara praktis memberikan panduan strategis bagi perusahaan dan regulator dalam merancang kebijakan transformasi digital yang berkelanjutan dan sesuai regulasi. Oleh karena itu, hasil penelitian ini memberikan kontribusi penting dalam memperkuat kerangka konseptual dan implementasional transformasi digital di sektor farmasi global.

Kata kunci: Transformasi Digital, Manufaktur Farmasi, Praktik Manufaktur yang Baik (GMP), Integritas Data, Efisiensi Operasional.

DOI:
https://doi.org/10.47134/scpr.v2i4.5068
*Correspondence: Susilowati Andari
Email: susilowati.akafarma@gmail.com

Received: 22-11-2025
Accepted: 22-12-2025
Published: 22-01-2026

Abstract: *This study aims to analyze the role of digital transformation in pharmaceutical manufacturing processes based on Good Manufacturing Practice (GMP) with a focus on its contribution to quality improvement, operational efficiency, and regulatory compliance. The study uses a qualitative approach with a descriptive method through a literature review, which involves analysis of scientific articles, official reports, and relevant academic documents published between 2015 and 2025. Data collection techniques were carried out through systematic searches of literature from various academic databases, while data analysis was conducted through the stages of theme identification, data reduction, concept categorization, and inductive conclusion drawing. The results of the study show that the integration of digital technologies such as Artificial Intelligence (AI), Internet of Things (IoT), blockchain, digital twins, and big data analytics significantly improves the effectiveness of GMP implementation by strengthening data integrity, accelerating data-driven decision making, and increasing the transparency of the pharmaceutical supply chain. However, obstacles such as organizational resistance, limitations of legacy system integration, and cybersecurity issues remain major challenges in its implementation. Theoretically, this study expands the understanding of the evolution of digital-based quality systems in the pharmaceutical industry, while practically providing strategic guidance for companies and regulators in designing sustainable and regulatory-compliant digital transformation policies. Thus, the results of this study make an important contribution to strengthening the conceptual and implementational framework of digital transformation in the global pharmaceutical sector.*

Keywords: *Digital Transformation, Pharmaceutical Manufacturing, Good Manufacturing Practice (GMP), Data Integrity, Operational Efficiency.*

Introduction

Digital transformation has become a major catalyst in changing the manufacturing industry landscape, including the highly regulated and quality-oriented pharmaceutical sector. In this context, the application of digital technology is not merely an operational tool, but a fundamental strategy in strengthening compliance with *Good Manufacturing Practice* (GMP) principles and improving production process efficiency. The integration of technologies such as *Artificial Intelligence* (AI), the Internet *of Things (IoT),* and *big* data *analytics* enables *real-time* monitoring of production processes and data-driven decision-making (Ullagaddi, 2024).

These developments are increasingly relevant given the global pressure on the pharmaceutical industry to accelerate innovation, maintain product quality, and comply with increasingly stringent international regulations. According to Tian et al. (2023), digital transformation practices significantly improve operational efficiency through process automation and reduction of human error, which directly impacts the improvement of pharmaceutical product quality and safety (Tian et al, 2023).

Global trends show that investment in digital technology in the pharmaceutical sector has increased sharply in the last five years, in line with the increasing need for robust and adaptive production systems after the COVID-19 pandemic (Miozza et al., 2024). This transformation involves not only the adoption of new technologies, but also changes in organizational culture and data governance in line with GMP standards (Vrdoljak, 2022).

The urgency of digital transformation becomes increasingly evident as the industry faces significant challenges such as supply chain complexity, cost pressures, and dynamic regulatory demands. In this context, the application of digitalization can strengthen data *integrity* and facilitate the audit and validation processes of computerized systems (Ullagaddi, 2024). This makes digitalization not only a technological innovation but also a strategic necessity in ensuring business sustainability and legal compliance.

However, the implementation of digital transformation in the pharmaceutical manufacturing environment is not without major challenges. The integration of old systems, the digital skills gap in human resources, and cybersecurity issues are the main obstacles that need to be overcome (Chirumalla et al, 2025). According to Hole et al. (2021), without a well-thought-out implementation strategy and strong internal policy support, digitization can actually create new risks related to data validity and production process disruptions (Hole et al, 2021).

One important breakthrough in supporting efficiency and compliance is the application of the digital *twin* concept, which is a virtual replication of the production process that enables simulation and optimization of manufacturing parameters (Chen et al, 2023) . This technology supports the *Quality by* Design (QbD) approach, which is aligned with GMP principles to produce more consistent and controlled processes (Aru et al, 2024).

In addition, the use of *blockchain* and *cloud computing* also plays a strategic role in maintaining supply chain transparency and cross-departmental data integration (Kodumuru et al., 2025). With *blockchain*, transaction data can be permanently recorded and cannot be manipulated, thereby increasing trust and integrity in the pharmaceutical production system (Ullagaddi, 2024).

Although various studies have highlighted the enormous potential of digital transformation, gaps remain in terms of organizational readiness and regulatory harmonization. Many companies are still struggling to integrate conventional systems with new technologies and to align strict GMP standards with the demands of digital flexibility (Miozza et al, 2024). These challenges indicate that the success of digital transformation is not only determined by technology, but also by the readiness of the supporting ecosystem and regulations.

In addition to technical challenges, resistance to change among workers is a significant obstacle. As stated in (Chirumalla et al, 2025), organizational cultural change requires a systematic change management approach to ensure effective technology adoption without sacrificing productivity. This emphasizes the importance of training and developing digital competencies for human resources in the pharmaceutical industry.

Furthermore, the application of AI in the context of GMP enables machine learning-based quality control systems that can detect anomalies early on (Nagy et al., 2022). This not only reduces the risk of product defects but also strengthens *real-time release testing* (RTRT), which is an important pillar in the concept of *continuous manufacturing* (Ntamo et al., 2022).

Macro-wise, digital transformation also has an impact on the global competitiveness of the pharmaceutical industry. Countries and companies that are quicker to adopt digital technology have the potential to gain a competitive advantage in terms of cost efficiency, product quality, and time to market (Tian et al, 2023). Therefore, digitization is not only an internal strategy but also a geopolitical instrument in ensuring national pharmaceutical independence.

However, the adoption of digitalization must still pay attention to ethical aspects and the security of patient data and manufacturing processes. Chen et al. (2020) emphasize that every digital system used in a GMP environment must undergo a thorough validation process to ensure the reliability and accuracy of data (Chen et al., 2020). Failure to maintain data integrity can have serious legal and *reputational* implications for pharmaceutical companies.

The main gap that this study focuses on is the lack of comprehensive integration between digital technology and GMP standards. Although various studies have highlighted the benefits of digitization, there are still limitations in the practical understanding of how technologies such as AI, *IoT*, and digital *twins* can be effectively applied without compromising regulatory compliance (Ghavat et al, 2024).

This article aims to analyze the dynamics of digital transformation in GMP-based pharmaceutical manufacturing processes, focusing on technology trends, implementation challenges, and success strategies. The discussion will integrate theoretical and practical perspectives to provide a holistic understanding of how digital transformation can support quality, efficiency, and compliance in the modern pharmaceutical industry.

Theoretically, this article is expected to enrich the literature on the relationship between digitization and GMP-based quality management systems. Practically, the results of this study are expected to provide strategic guidance for pharmaceutical companies in designing an effective, sustainable, and internationally compliant digital transformation roadmap. Thus, digital transformation can become the foundation for creating a more

adaptive, innovative, and highly competitive pharmaceutical manufacturing ecosystem in the Industry 4.0 era.

Methodology

The article "Digital Transformation in *Good Manufacturing* Practice-Based Pharmaceutical Manufacturing Processes" uses a qualitative approach with descriptive methods through *library* research. This approach was chosen because it is suitable for exploring and understanding in depth the phenomenon of digital transformation in the context of pharmaceutical manufacturing based on *Good Manufacturing Practice* (GMP). Qualitative research aims to produce a contextual understanding of social reality through systematic descriptions based on the researcher's interpretation of various literature sources (Bingham, 2023) (Pratt, 2025).

The data sources in this study were obtained entirely from credible secondary literature, including academic books, scientific articles from reputable international journals, and official reports relevant to the theme of pharmaceutical industry digitization and GMP implementation. The literature used includes empirical and conceptual research results that discuss the role of technologies such as *Artificial Intelligence (*AI), Internet *of Things (IoT),* Digital *Twin,* and *Blockchain* in supporting the efficiency and compliance of pharmaceutical manufacturing. Sources were selected based on publisher credibility, journal reputation, and thematic relevance to the issues of digital transformation and GMP-based quality management.

Data collection techniques were carried out through systematic literature searches. The researchers searched academic databases such as Scopus, ScienceDirect, and SpringerLink to obtain the latest references relevant to the research topic. The literature study approach allowed for critical analysis of theories, concepts, and previous research results without direct interaction with empirical subjects (Jimenez et al, 2024) (Togia & Malliari, 2017). Through the analysis of credible documents and academic sources, this study is able to examine the development of the concept of digitalization in the pharmaceutical industry and identify gaps between theory and practice.

The data analysis procedure was carried out systematically through several main stages. The first stage was theme identification by selecting the main topics from each source related to digital transformation and GMP implementation. The second stage was data reduction, which involved filtering the most relevant information to answer the research questions. The third stage was concept categorization, in which the data was classified into themes such as operational efficiency, product quality, and regulatory compliance (Chen et al, 2020) (Tian et al, 2023). The final stage is inductive conclusion drawing, integrating findings from various sources to produce a comprehensive understanding of the phenomenon under study (Bingham, 2023) (Fife & Gossner, 2024).

The literature inclusion criteria include scientific works published between 2015 and 2025, focusing on digital transformation in the manufacturing or pharmaceutical sector, and relevant to the context of GMP implementation. Meanwhile, exclusion criteria include sources that have not undergone *peer review* or that do not contain empirically or conceptually accountable information (Miozza et al, 2024). The selection process was carried

out carefully to ensure that the data used was valid and able to reflect the latest developments in this field of research.

To maintain the validity and reliability of the data, this study applied source triangulation techniques, which involve comparing findings from various literature to ensure consistency of information and reliability of interpretation (Belotto, 2018) (Kalpokaite & Radivojevic, 2018). In addition, *a* conceptual *peer review* was conducted, which is a cross-check of the analysis results with the theory and conceptual framework from previous studies to avoid interpretive bias (Abraham & P, 2024) (Doyle et al, 2019). Thus, the qualitative-descriptive approach through this literature review yields a thorough, valid, and accountable analysis, while supporting the research objective of understanding the strategies, challenges, and opportunities of digital transformation in GMP-based pharmaceutical manufacturing processes.

Result and Discussions

The results of the literature study on "The Role of Digital Transformation in *Good Manufacturing Practice* (GMP)-Based Pharmaceutical Manufacturing Processes" show that digitalization has become a key factor in improving quality, efficiency, and regulatory compliance in the global pharmaceutical industry. Based on findings from various recent studies, the integration of digital technologies such as the Internet *of Things (IoT), Artificial Intelligence* (AI), digital *twins, big* data *analytics,* and *cloud computing* plays a major role in driving automation and optimization of pharmaceutical production processes (Gong et al, 2025) (Ntamo et al, 2022) (Soni & Patel, 2024). These technologies support the implementation of GMP principles by enabling *real-time* process monitoring, early detection of quality deviations, and improved accuracy of data underlying decision-making (Ullagaddi, 2024).

Empirically, research results show that digital transformation has a significant impact on product quality and patient safety. The implementation of *electronic batch records* (EBR) and *manufacturing execution systems* (MES) has been proven to reduce the potential for human error in the production process and strengthen integrity (Hole et al., 2021; Ullagaddi, 2024). In addition, *blockchain* and radio *frequency identification* (RFID) technologies play an important role in strengthening *traceability* and preventing product counterfeiting, which is one of the major challenges in the global pharmaceutical supply chain (Jing et al, 2022).

The next finding shows that digitization also has a real impact on operational efficiency. By adopting a *predictive maintenance* approach and *IoT-based* monitoring, pharmaceutical companies can extend the life of their equipment, reduce production downtime, and reduce maintenance costs (Gong et al, 2025) (Vesnap & Koshechkin, 2024). Meanwhile, *cloud* computing-based systems enable fast and secure cross-departmental data access, fostering inter-team collaboration and more responsive decision-making (Ullagaddi, 2024).

However, the study also identified several key challenges in implementing digital transformation. The most common obstacles include integration with legacy systems, lack of data standardization, organizational resistance to change, and cybersecurity threats (Soni & Patel, 2024) (Ullagaddi, 2024). Research Ramanamuni (2024) confirms that the success of

digital transformation in the pharmaceutical industry is highly dependent on management's commitment to technology investment and the development of a culture of innovation in the work environment (Ramanamuni, 2024).

From a practical perspective, a number of case studies demonstrate successful implementation models. Ntamo et al. (2022) report that the application of digital *twins* in the pharmaceutical product formulation process enables simulated and *real-time* quality control (Ntamo et al, 2022), while Muchamatgaleeva (2023) developed a three-phase digital transformation model that includes the stages of engineering design, technical transformation, and active digital system development (Muchamatgaleeva, 2023). Research by Kuzmina et al. (2024) also shows how planned digitalization project management can improve cross-departmental coordination and accelerate the adoption of digital systems in pharmaceutical production (Kuzmina et al, 2024).

Table 1. The Role of Digital Transformation in Pharmaceutical Manufacturing Processes Based on *Good Manufacturing Practice* (GMP)

Aspect	Key Impact	Source
Quality & Safety	Improved product quality, reduced human *error*, enhanced *traceability*	(Hole et al., 2021; Jing et al., 2022; Ullagaddi, 2024)
Operational Efficiency	Automation, *real-time* monitoring, *predictive maintenance*	(Gong et al., 2025; Ntamo et al., 2022; Vesnap & Koshechkin, 2024)
Regulatory Compliance	Data integrity enhancement, automated audit trails, reduction of sanction risks	(Soni & Patel, 2024; Ullagaddi, 2024)
Implementation Challenges	Integration of legacy systems, organizational resistance, data security issues	(Ramanamuni, 2024; Soni & Patel, 2024; Ullagaddi, 2024)

Compared to previous research, this study shows significant progress in the more comprehensive application of digital technology and a focus on integrating GMP systems with the digital ecosystem. While previous studies still focused on process automation, the latest results show improvements in data *integrity* management and cross-functional collaboration based on smart systems . Thus, the results of this study confirm that digital transformation not only improves technical performance but also strengthens quality management and transparency in the global pharmaceutical industry.

Discussion

Digital transformation in *Good Manufacturing Practice* (GMP)-based pharmaceutical manufacturing is a tangible manifestation of the application of Industry 4.0 principles in the most regulated and high-risk sector. Based on the results of a literature review, it can be concluded that the adoption of digital technology is not only instrumental but also transformative in creating efficiency, transparency, and quality improvement throughout the drug production cycle . The application of technologies such as *Artificial Intelligence* (AI), Internet *of Things* (*IoT*), *big* data *analytics*, digital *twins*, and *blockchain* reinforces GMP principles by enabling production systems that are more resilient, predictive, and adaptive to market dynamics and global regulations (Ullagaddi, 2024).

From the perspective *of* Total *Quality* Management theory, digitalization expands the concept *of continuous improvement* by providing *real-time* data and predictive analytics that accelerate *the feedback loop* between quality control and process improvement. For example, *electronic batch records* (EBR) and *manufacturing execution systems* (MES) serve as key pillars in supporting data *integrity*, which is a critical component of GMP regulations (Hole et al., 2021). These findings are consistent with the theory of *Quality by* Design (QbD), where quality control is carried out from the process design stage, not just at the final result.

The results also show that *blockchain* and radio *frequency identification* (RFID) technologies expand the scope of compliance by strengthening *the traceability* of pharmaceutical products from raw materials to final distribution (Jing et al, 2022). The implications of these findings are significant, especially in the context of the global *supply chain*, as they enhance patient safety through early detection of counterfeit drugs and facilitate regulatory audits. This supports a new GMP paradigm that emphasizes *data-driven compliance*, not just manual documentation.

However, the research results also reveal a significant gap between technological readiness and organizational readiness. Factors such as resistance to change, limited digital literacy, and problems with integrating legacy systems remain major obstacles (Soni & Patel, 2024) (Ullagaddi, 2024). Conceptually, this refers to the *Technology-Organization-Environment* (TOE) *framework* theory, which asserts that the success of digital transformation depends on the synergistic interaction between technological readiness, organizational support, and regulatory context. A lack of balance between these three factors leads to inefficient adoption even when the technology used is state-of-the-art.

In the context of strategic management, the findings of Gong et al. (2025) and Ramanamuni (2024) show that the success of digitalization in pharmaceutical manufacturing cannot be separated from long-term investment strategies and top management support (Gong et al, 2025). Organizations that successfully undergo digital transformation generally adopt a *top-down* approach in building a culture of innovation and data security. Conversely, companies that only focus on technological aspects without strengthening human resource competencies face the risk of implementation failure. Therefore, digital transformation should be viewed as a cross-functional strategic investment, not merely a technology project.

Although the benefits of digital transformation are proven to be significant, this study also has limitations. Most of the studies analyzed are still based on case study or conceptual model approaches, so generalizations to various contexts in the pharmaceutical industry need to be made with caution. In addition, cybersecurity and data protection factors have not been explored in depth, even though these aspects are crucial in a *cloud-based* production environment. For future research, it is recommended that a multi-country empirical approach be used to examine the relationship between digitization, product quality, and GMP compliance using statistical models or *structural equation* modeling, as done by (Jing et al, 2022).

Overall, these results and analyses reinforce the position of digital transformation as a strategic element in the evolution of the modern pharmaceutical industry. The integration of digital technology into GMP systems not only improves efficiency and quality but also

shifts the compliance paradigm from reactive to proactive and data-driven. Thus, this research makes an important contribution to the development of digital *quality management* theory and practice and provides a conceptual foundation for policymakers and industry players in designing sustainable digitalization strategies in the pharmaceutical sector.

Conclusion

This qualitative study concludes that digital transformation in *Good Manufacturing Practice* (GMP)-based pharmaceutical manufacturing processes plays a crucial role in strengthening data integrity, operational efficiency, and regulatory compliance through the adoption of technologies such as *Artificial Intelligence* (AI), Internet *of Things (IoT), blockchain,* digital *twins,* and *big* data *analytics*. The results of the analysis show that digitization not only improves the quality of and product safety, but also revolutionizes the quality control paradigm from a reactive approach to *data-driven proactive control* (Gong et al., 2025; Hole et al., 2021). These findings deepen the understanding of *Quality by* Design (QbD) and Total *Quality Management* (TQM) theories by emphasizing that digital transformation is a systemic evolution from manual-based quality practices to adaptive and integrated intelligent automation (Ullagaddi, 2024). Socially and culturally, this transformation reflects a shift in work values in the pharmaceutical sector towards a data-driven ecosystem, digital collaboration, and greater regulatory transparency (Ramanamuni, 2024). Academically, this research expands the discourse on digitalization in *highly regulated* industries by highlighting the importance of synergy between technology, human resources, and organizational policies. However, the limitations of this study lie in the dominance of conceptual sources and case studies, thus requiring cross-country empirical research to validate the relationship between digitization, GMP effectiveness, and global competitiveness. Future research can be directed toward developing an integrative model that links digital *maturity* levels with regulatory compliance and its impact on the sustainability of the global pharmaceutical industry. The study recommends accelerating the integration of digital technologies with *Good Manufacturing Practice* through strengthened data infrastructure, digital competencies, cyber security governance, and adaptive regulations, while encouraging academics and future studies to develop robust models and triangulated evidence on the impact of digital maturity on quality systems, efficiency, and sustainability in the pharmaceutical industry era 5.0.

References

Abraham, D., & P, P. (2024). A Methodological Framework for Descriptive Phenomenological Research. *Western Journal of Nursing* Research, *47*

Aru, P. B., Gulhane, M. S., Katekar, V. A., & Deshmukh, S. P. (2024). Quality by Design (QbD) in pharmaceutical development: A comprehensive review. *GSC Biological and Pharmaceutical Sciences*. https://doi.org/10.30574/gscbps.2024.26.1.0019

Belotto, M. (2018). Data Analysis Methods for Qualitative Research: Managing the Challenges of Coding, Interrater Reliability, and Thematic Analysis. *The Qualitative Report*. https://doi.org/10.46743/2160-3715/2018.3492

Bingham, A. (2023). From Data Management to Actionable Findings: A Five-Phase Process of Qualitative Data Analysis. *International Journal of Qualitative Methods*, *22* . https://doi.org/10.1177/16094069231183620

Chen, Y., Sampat, C., Huang, Y., Ganesh, S., Singh, R., Ramachandran, R., Reklaitis, G., & Ierapetritou, M. (2023). An integrated data management and informatics framework for continuous drug product manufacturing processes: A case study on two pilot plants. *International Journal of Pharmaceutics*. https://doi.org/10.1016/j.ijpharm.2023.123086

Chen, Y., Yang, O., Sampat, C., Bhalode, P., Ramachandran, R., & Ierapetritou, M. (2020). Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review. *Processes*. https://doi.org/10.3390/pr8091088

Chirumalla, K., Oghazi, P., Nnewuku, R., Tuncay, H., & Yahyapour, N. (2025). Critical factors affecting digital transformation in manufacturing companies. *International Entrepreneurship and Management Journal*. https://doi.org/10.1007/s11365-024-01056-3

Doyle, L., McCabe, C., Keogh, B., Brady, A., & McCann, M. (2019). An overview of the qualitative descriptive design within nursing research. *Journal of Research in* Nursing, *25*

Fife, S., & Gossner, J. (2024). Deductive Qualitative Analysis: Evaluating, Expanding, and Refining Theory. *International Journal of Qualitative* Methods, *23*

Ghavat, K., Wakchoure, S., Surve, P., & Hole, N. (2024). Review on Digital Twin in Pharmaceutical and Biopharmaceutical Manufacturing. *International Journal of Scientific Research in Science and Technology*. https://doi.org/10.32628/ijsrst241161127

Gong, S., Kim, H., Park, Y., & Kim, J. (2025). Recent trends in continuous manufacturing and digitalization in pharmaceutical process development and manufacturing. *Journal of Pharmaceutical Investigation*. https://doi.org/10.1007/s40005-025-00728-8

Hole, G., Hole, A. S., & McFalone-Shaw, I. (2021). Digitalization in the pharmaceutical industry: What to focus on under the digital implementation process? *Heliyon*, *7* (3), e06552.

Jimenez, S., Berbegal-Mirabent, J., & De La Torre, R. (2024). How do university libraries contribute to the research process? *The Journal of Academic Librarianship*. https://doi.org/10.1016/j.acalib.2024.102930

Jing, J., Shi, L., & Kang, T. (2022). The Effect of Digital Transformation on the Pharmaceutical Sustainable Supply Chain Performance: The Mediating Role of Information Sharing and Traceability Using Structural Equation Modeling. *Sustainability*. https://doi.org/10.3390/su15010649

Kalpokaite, N., & Radivojevic, I. (2018). Demystifying Qualitative Data Analysis for Novice Qualitative Researchers. *The Qualitative Report*. https://doi.org/10.46743/2160-3715/2019.4120

Kodumuru, R., Sarkar, S., Parepally, V., & Chandarana, J. (2025). Artificial Intelligence and Internet of Things Integration in Pharmaceutical Manufacturing: A Smart Synergy. *Pharmaceutics*. https://doi.org/10.3390/pharmaceutics17030290

Kuzmina, K., Smeshko, O., Nosova, Y., & Borisova, S. (2024). Experience of Digitalization Project Management in a Pharmaceutical Production Company. *Economics and Management: Problems, Solutions.* https://doi.org/10.36871/ek.up.p.r.2024.01.02.002

Miozza, M., Brunetta, F., & Appio, F. (2024). Digital transformation of the Pharmaceutical Industry: A future research agenda for management studies. *Technological Forecasting and Social Change*. https://doi.org/10.1016/j.techfore.2024.123580

Muchamatgaleeva, L. R. (2023). Model of digital transformation of the organization of production for enterprises in the pharmaceutical industry. *Economics and Management*, *25*(1), 10–16.

Nagy, B., Galata, D., Farkas, A., & Nagy, Z. (2022). Application of Artificial Neural Networks in the Process Analytical Technology of Pharmaceutical Manufacturing—A Review. *The AAPS Journal*. https://doi.org/10.1208/s12248-022-00706-0

Ntamo, D., Lopez-Montero, E., Mack, J., Omar, C., Highett, M., Moss, D., Mitchell, N., Soulatintork, P., Moghadam, P., & Zandi, M. (2022). Industry 4.0 in Action: Digitalization of a Continuous Process Manufacturing for Formulated Products. *Digital Chemical Engineering.* https://doi.org/10.1016/j.dche.2022.100025

Pratt, M. (2025). On the Evolution of Qualitative Methods in Organizational Research. *Annual Review of Organizational Psychology and Organizational Behavior*. https://doi.org/10.1146/annurev-orgpsych-111722-032953

Ramanamuni, S. (2024). Digital Transformation: A Critical Component for CDMOs in the Pharmaceutical Industry. *International Journal on Science and Technology*. https://doi.org/10.71097/ijsat.v15.i4.2834

Soni, S., & Patel, A. (2024). Digital transformation and industry 4.0 in pharma manufacturing: The role of IoT, AI, and big data. *Journal of Integral Sciences*. https://doi.org/10.37022/jis.v7i4.92

Tian, M., Chen, Y., Tian, G., Huang, W., & Hu, C. (2023). The role of digital transformation practices in the operations improvement in manufacturing firms: A practice-based view. *International Journal of Production Economics*. https://doi.org/10.1016/j.ijpe.2023.108929

Togia, A., & Malliari, A. (2017). *Research Methods in Library and Information Science*. https://doi.org/10.5772/intechopen.68749

Ullagaddi, P. (2024). Digital transformation in the pharmaceutical industry: Enhancing quality management systems and regulatory compliance. *International Journal of Health Sciences*, *12*(1), 45–59.

Vesnap, O., & Koshechkin, K. (2024). Computerization of pharmaceutical production. *Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)*. https://doi.org/10.33920/med-13-2404-03

Vrdoljak, A. (2022). Objectivization of virus titration method in GMP-regulated environment using artificial intelligence-based classification system. *European Journal of Pharmaceutics and Biopharmaceutics*. https://doi.org/10.1016/j.ejpb.2022.11.020